Lawrence I. Karsh, MD, addresses the problem of long-term complications following prostate radiation therapy and describes how a novel absorbable hydrogel spacer can alleviate these issues. Additionally, he describes how the spacer can improve conventional radiology, enable dose escalation as well as salvage therapy and hypofractionation, and improve the safety of these patients.Read More
Lawrence Karsh, MD
The Urology Center of Colorado
Lawrence I. Karsh, MD, is a co-founder of The Urology Center of Colorado, where he serves as an attending urologist and Director of Research & Co-Chairman of Advanced Therapeutic Clinic. He is a certified principal investigator, and has been the principal investigator for over 250 clinical trials. He has authored a number of peer-reviewed publications and serves on the editorial boards for Oncology Live, Urologists in Cancer Care, and Bladder Cancer. He is a fellow of the American College of Surgeons, and an active member AUA, SUO, ASCO, SWOG, ACS, and the Denver Academy of Surgeons. He serves on the bladder cancer subcommittee and is on the advisory board for the SUO Clinical Trials Consortium and a member of the Bladder Cancer Advocacy Network (BCAN) Think Tank. Dr. Karsh completed his General Surgery training at The University of Colorado Health Sciences Center (UCHSC) and his Urology residency at Brigham and Women's Hospital/Harvard Medical School. He is an Associate Clinical Professor of Surgery at UCHSC. Dr. Karsh participates in many advisory boards for new drug development. He lectures and teaches at scientific meetings throughout the country.
Articles by Lawrence Karsh, MD
Posted by Lawrence Karsh, MD | May 2018
Lawrence I. Karsh, MD, FACS, discusses the use of SpaceOAR Hydrogel to reduce risk of rectal complications and improve quality of life (QOL) outcomes when treating prostate cancer with radiation therapy. He summarizes supporting clinical evidence, describes the physical application of the gel, and lists players currently offering coverage for the procedure.Read More
Posted by Lawrence Karsh, MD | Apr 2018
Lawrence Karsh, MD, FACS, argues that agonists are effective, sustainable androgen deprivation therapy (ADT) options, and the belief that agonists present a high cardiovascular (CV) risk could be due to selection bias in trials. Conversely, Thomas Keane, MD, argues that patients treated with antagonists have lower CV risk and are more responsive to ADT than those treated with agonists.Read More
Ask the Expert: What Are Some of the Challenges for Urologists Treating Metastatic Castrate Resistant Prostate Cancer Patients?
Posted by Lawrence Karsh, MD | Nov 2017
Lawrence Karsh, MD, The Urology Center of Colorado, Denver, Colorado, discusses what some of the...Read More
Ask the Expert: How Do Urologists and Medical Oncologists Differ in Their Approach to Prostate Cancer?
Posted by Lawrence Karsh, MD | Oct 2017
Lawrence Karsh, MD, The Urology Center of Colorado, Denver, Colorado, discusses how urologists and...Read More